You are here » Home » Companies » Company Overview » Novartis India Ltd

Novartis India Ltd.

BSE: 500672 Sector: Health care
NSE: NOVARTIND ISIN Code: INE234A01025
BSE 12:26 | 16 May 585.95 0
(0.00%)
OPEN

585.05

HIGH

591.85

LOW

584.10

NSE 12:14 | 16 May 584.25 -2.70
(-0.46%)
OPEN

593.00

HIGH

593.00

LOW

580.85

OPEN 585.05
PREVIOUS CLOSE 585.95
VOLUME 167
52-Week high 1099.00
52-Week low 574.15
P/E 49.28
Mkt Cap.(Rs cr) 1,447
Buy Price 583.30
Buy Qty 50.00
Sell Price 587.20
Sell Qty 3.00
OPEN 585.05
CLOSE 585.95
VOLUME 167
52-Week high 1099.00
52-Week low 574.15
P/E 49.28
Mkt Cap.(Rs cr) 1,447
Buy Price 583.30
Buy Qty 50.00
Sell Price 587.20
Sell Qty 3.00

Novartis India Ltd. (NOVARTIND) - Chairman Speech

Company chairman speech

In the second year of the pandemic there is light at the end of the tunnel. While morethan 4.0 million lives have been lost in the global outbreak with vaccination drivesacross the world gathering momentum the end of this very difficult period seems to be insight.

While the severity and rapid spread of the pandemic took everyone by surprise as arepresentative of the industry I’m happy to note that the pharmaceutical andhealthcare sectors were impressive in their response to the challenge. The remarkable andunprecedented collaborative efforts across both industry and geographic lines helped tofuel extraordinary innovation in drug and vaccine discovery development clinical trialsacceleration and production. This collaboration extended to keeping supply chains workingso that patients of both COVID-19 as well as other diseases continue to get treatment andmedicines.

While companies felt the initial impact of the pandemic some of them quickly realignedtheir businesses to meet the obstacles head-on. Certainly Novartis both at the globallevel and in India saw change at every level from manufacturing to supply chains tocustomer engagement among other areas.

Emerging digital technologies played a key role in this. Artificial Intelligence (AI)and Big Data are already aiding drug discovery and development. They are also provinguseful in clinical trials and fraud detection among other things. The pandemic-inducedcrisis further enhanced their use. These technologies also made life a little easier forpatients during the pandemic all over the world but especially in India by enablinge-pharmacies and online consultations. These trends are only likely to strengthen.

Looking beyond the pandemic I think what the COVID-19 outbreak has done is tohighlight several deficiencies within the global health infrastructure. This is especiallytrue of India where public spending on healthcare is among the lowest in the BRICS andOECD countries. For India to achieve the target of USD 5 trillion GDP in the next fewyears it is critical that the government invests far more in the sector. In itsmemorandum submitted to the Government before the FY21-22 budget the Confederation ofIndian Industries (CII) had recommended that the spend towards healthcare beboosted to at least 2.5% to 3% of the GDP.

In its report the 15th Finance Commission has noted the severe disparitiesbetween Indian states on healthcare funding and availability of infrastructure. It hasrecommended a robust framework of public-private partnership in the sector. Hopefully oncethe COVID-19 crisis is past us this initiative will be pursued with purpose andconviction.

For Novartis we will continue to build on our learnings over the last year and a half.This annual report provides a glimpse into how we overcame challenges to reimagine oursupply chain in the country and ensure last mile delivery of our medicines to patients.

On behalf of the Board of Directors I am pleased to continue with our steady dividendpolicy and propose a dividend of 10 per equity share of 5 at the forthcoming AnnualGeneral Meeting.

Thank you for your continued confidence in our Company. I look forward to the same inthe years ahead.

Sincerely

Christopher Snook

Chairman

.